Stay updated on Pembrolizumab Combo in Triple Negative Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Triple Negative Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Triple Negative Breast Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedAdded a consolidated Locations section listing nine study sites across Kansas, Missouri, and Texas, replacing the previous state-specific sections (Kansas Locations, Missouri Locations, Texas Locations). The page revision updated to v3.3.3.SummaryDifference0.4%

- Check25 days agoNo Change Detected
- Check47 days agoChange DetectedUpdated UI text to indicate PubMed publications are automatically filled and may not pertain to the study, and changed the revision label from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check54 days agoChange DetectedThe government funding lapse and NIH operating status banner was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check68 days agoChange DetectedThe screenshots show only minor formatting and layout adjustments to the study page; core details such as title, conditions, interventions, and outcomes remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check97 days agoChange Detected- Added a government operating status notice and links to cc.nih.gov and opm.gov. - Bumped revision from v3.1.0 to v3.2.0.SummaryDifference4%

- Check104 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Combo in Triple Negative Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Triple Negative Breast Cancer Clinical Trial page.